Imperial College London
Portrait Picture

DrJonathanKrell

Faculty of Medicine, Department of Surgery & Cancer

Clinical SL in Medical Oncology (Gynaecological Oncology)
 
 
 
//

Contact

 

j.krell

 
 
//

Location

 

Institute of Reproductive and Developmental BiologyHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Carter:2018:10.18632/oncotarget.24258,
author = {Carter, P and Alifrangis, CC and Cereser, B and Chandrasinghe, P and Del, Bel Belluz L and herzog, T and levitan, J and Moderau, N and Schwartzberg, L and Tabassum, N and Wen, J and Krell, J and Stebbing, J},
doi = {10.18632/oncotarget.24258},
journal = {Oncotarget},
pages = {9456--9467},
title = {Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients?},
url = {http://dx.doi.org/10.18632/oncotarget.24258},
volume = {9},
year = {2018}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - We evaluated the effect of tailoring treatments based on predictions informed by tumor molecular profiles across a range of cancers, using data from Caris Life Sciences. These included breast carcinoma, colorectal adenocarcinoma, female genital tract malignancy, lung non-small cell lung cancer, neuroendocrine tumors, ovarian surface epithelial carcinomas, and urinary tract cancers.Molecular profiles using mostly immunohistochemistry (IHC) and DNA sequencing for tumors from 841 patients had been previously used to recommend treatments; some physicians followed the suggestions completely while some did not. This information was assessed to find out if the outcome was better for the patients where their received drugs matched recommendations.The IHC biomarker for the progesterone receptor and for the androgen receptor were found to be most prognostic for survival overall. The IHC biomarkers for P-glycoprotein (PGP), tyrosine-protein kinase Met (cMET) and the DNA excision repair protein ERCC1 were also shown to be significant predictors of outcome. Patients whose treatments matched those predicted to be of benefit survived for an average of 512 days, compared to 468 days for those that did not (P = 0.0684). In the matched treatment group, 34% of patients were deceased at the completion of monitoring, whereas this was 47% in the unmatched group (P = 0.0001).
AU  - Carter,P
AU  - Alifrangis,CC
AU  - Cereser,B
AU  - Chandrasinghe,P
AU  - Del,Bel Belluz L
AU  - herzog,T
AU  - levitan,J
AU  - Moderau,N
AU  - Schwartzberg,L
AU  - Tabassum,N
AU  - Wen,J
AU  - Krell,J
AU  - Stebbing,J
DO  - 10.18632/oncotarget.24258
EP  - 9467
PY  - 2018///
SN  - 1949-2553
SP  - 9456
TI  - Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients?
T2  - Oncotarget
UR  - http://dx.doi.org/10.18632/oncotarget.24258
UR  - http://hdl.handle.net/10044/1/56271
VL  - 9
ER  -
Download